Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TAF1 | P21675 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505502 | 0.78 | FGFR1 (0.38) | CDK8LRRK2FYNPIP5K1CPIK3CA | |
| SCHEMBL3645569 | 0.74 | CDK8 (0.43) | CDK8CRBNLRRK2BRD4CREBBP | |
| SCHEMBL13702375 | 0.72 | HDAC8 (0.68) | CDK8HDAC8HDAC6MAP4K4CRBN | |
| SCHEMBL723332 | 0.68 | HDAC8 (0.70) | CDK8HDAC8HDAC6CRBNPDK2 | |
| SCHEMBL5909363 | 0.67 | HDAC8 (0.83) | CDK8HDAC8HDAC6CREBBPSLC7A5 | |
| SCHEMBL9056834 | 0.67 | CRBN (0.61) | CDK8HDAC8HDAC6CRBNCYP17A1 | |
| SCHEMBL3037788 | 0.67 | HDAC8 (0.82) | CDK8HDAC8HDAC6MAP4K4CRBN | |
| SCHEMBL30262680 | 0.65 | HDAC8 (0.53) | CDK8HDAC8HDAC6MAP4K4CRBN | |
| SCHEMBL3617485 | 0.65 | CRBN (0.56) | CDK8HDAC8HDAC6CRBNCYP17A1 | |
| SCHEMBL14210412 | 0.65 | CRBN (0.58) | CDK8HDAC8HDAC6CRBNCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188285-A1 | PYRAZOLOQUINOLINE AND PYRAZOLONAPHTHYRIDINE DERIVATIVES AS GABA ALPHA LIGANDS | Novartis Ag (CH) | 2010-05-26 | — | — | EP | claimed |
| WO-2009021961-A1 | PYRAZOLOQUINOLINE AND PYRAZOLONAPHTHYRIDINE DERIVATIVES AS GABA ALPHA LIGANDS | NOVARTIS AG (CH) | 2009-02-19 | — | — | WO | claimed |
| CN-101765442-B | Organic compounds | NOVARTIS AG | 2014-09-17 | — | — | CN | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| CN-101765442-A | organic compounds | NOVARTIS AG | 2010-06-30 | — | — | CN | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | CDK8 1828/4885HDAC8 3212/4885HDAC6 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.